
FDA knocks back Glenmark’s allergic rhinitis therapy Ryaltris
pharmafile | June 25, 2019 | News story | Manufacturing and Production, Sales and Marketing | FDA, Glenmark, Ryaltris, US, allergy, pharma
Stocks in Indian pharmaceutical firm Glenmark were sent plummeting to a six-year low after it was confirmed that the FDA had raised concerns over the company’s New Drug Application for Ryaltris (olopatadinehydrochloride and mometasonefuroate) in the treatment of seasonal allergic rhinitis.
The company’s shares fell 7% when it announced via a short press release that it had received a Complete Response Letter from the US regulator. The company’s release noted that the FDA’s concerns centred on “deficiencies in the Drug Master File pertaining to one of the active pharmaceutical ingredients and in the manufacturing facilities.”
Beyond this, further details on the nature of these concerns or deficiencies were not given. However, Glenmark made it known that they were not related to the clinical data submitted in support of the Rylatris application.
Despite the setback, the drugmaker said they would continue to push for regulatory approval of the drug in collaboration with the FDA. “We feel confident that we should be able to resolve these issues within the next six to nine months,” the company said.
Matt Fellows
Related Content

EndoCyclic New Drug application approved by US FDA for endometriosis treatment
EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …

Coriolis Pharma opens new US headquarter and laboratory
Coriolis Pharma has opened a new US headquarter and laboratory at the Alexandria Center for …

Abselion establishes a US subsidiary in Massachusetts
Abselion has established a US subsidiary at The Engine in Cambridge, Massachusetts in the US. …





